# Bariatric surgery as a treatment of polycystic ovary syndrome: a systematic review and meta-analysis

**Authors:** Hyder Mirghani, Amani Shaman

PMC · DOI: 10.3389/fendo.2025.1682379 · Frontiers in Endocrinology · 2026-01-05

## TL;DR

Bariatric surgery helps reduce symptoms of polycystic ovary syndrome, such as menstrual issues and high testosterone, but more research is needed on long-term effects.

## Contribution

This study provides a systematic review and meta-analysis on the effects of bariatric surgery on PCOS symptoms and hormonal markers.

## Key findings

- Bariatric surgery significantly reduced menstrual irregularities and hirsutism in PCOS patients.
- The surgery lowered total and free testosterone, AMH, and LH levels while increasing SHBG.
- No significant effects were observed on FSH, birth weight, gestational age, or pre-term delivery.

## Abstract

Polycystic ovary syndrome (PCOS) is the most common endocrine disorder among females of reproductive age, and the majority are obese/overweight. PCOS management, including lifestyle and drugs, is limited by unsustainability and side effects. Bariatric surgery (BS) is promising in addressing hyperandrogenism and pregnancy outcomes. We aimed to assess the impact of bariatric surgery on PCOS components.

We systematically searched PubMed/MEDLINE, Google Scholar, Cochrane Library, and Web of Science during July and August 2025, articles from inception up to August 2025 were included. The keywords used were BS, sleeve gastrectomy, gastric bypass, gastric banding, menstrual irregularities, free testosterone, total testosterone, hirsutism, SHBG, lutenizing hormone, antimullarian hormone (AMH), follicle-stimulating hormone, and pre-term deliveries. 648 articles were eligible, 35 full texts were reviewed, and 27 were included in the final meta-analysis.

Bariatric surgery reduced menstrual irregularities and hirsutism, with odds ratios of 27.68, 95% CI, 9.83-78.00, and 6.61, 95% CI, 0.97-47.07, respectively. In addition, total testosterone, free testosterone, AMH, and LH were reduced, SD, -19.95, 95% CI, -28.53–11.38, SD, 2.40, 95% CI, 1.30.53-3.51, SD, 1.66, 95% CI, 0.17-3.14, and SD, 2.21, 95% CI, 1.73-2.69 respectively, while SHBG were increased. No effects were observed regarding FSH, birth weight, gestational age, and pre-term delivery.

BS reduced menstrual irregularities, hirsutism, total and free testosterone, AMH, and LH and increased SHBG. No significant differences were evident regarding other outcomes. Larger controlled trials investigating the long-term effects and the mechanism of action of BS on pregnancy outcomes, metabolic, and reproductive hormones are needed.

## Linked entities

- **Diseases:** Polycystic ovary syndrome (MONDO:0008487), obesity (MONDO:0011122)

## Full-text entities

- **Genes:** SHBG (sex hormone binding globulin) [NCBI Gene 6462] {aka ABP, SBP, TEBG}, AMH (anti-Mullerian hormone) [NCBI Gene 268] {aka MIF, MIS}
- **Diseases:** endocrine disorder (MESH:D004700), overweight (MESH:D050177), PCOS (MESH:D011085), hirsutism (MESH:D006628), hyperandrogenism (MESH:D017588), obese (MESH:D009765)
- **Chemicals:** testosterone (MESH:D013739)

## Full text

_Full body text omitted from this summary view._ Fetch the complete paper as Markdown: https://tomesphere.com/paper/PMC12812726/full.md

## Figures

10 figures with captions in the complete paper: https://tomesphere.com/paper/PMC12812726/full.md

## References

64 references — full list in the complete paper: https://tomesphere.com/paper/PMC12812726/full.md

---
Source: https://tomesphere.com/paper/PMC12812726